← Leaderboards
Adriana T Larregina
University Of Pittsburgh At Pittsburgh
$7,348,667
Attributed
$11,100,126
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,100,126 · 6
By mechanism
R01$10,654,438 · 5
R21$445,688 · 1
Top collaborators
- Louis D Falo10 shared
- Adrian E Morelli4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Louis D Falo$30,012,458
- Marlies Meisel$3,222,637
- Steven R Little$5,142,670
- Alicia R Mathers$4,373,803
- Adrian E Morelli$11,040,013
Others in their field
Top investigators on “Skin”
- David Heimbrook · Leidos Biomedical Research, Inc.$121,104,269
- Donald Ym Leung · University Of Colorado Denver$58,473,424
- Thomas S. Kupper · Dana-Farber Cancer Institute$53,329,207
- Elaine Fuchs · University Of Chicago$41,573,105
- Timothy Burgess · National Institute Of Allergy And Infectious Diseases$35,600,000
- David Leung · National Jewish Health$31,859,607
Research focus
SkinInflammatoryMediatingCellsGenerationsCutaneousSubstance PT-LymphocyteResponseSignal TransductionInflammationDendritic CellsExposure ToInflammation MediatorsNeuropeptidesSkin DisorderSubstance P ReceptorT Cell ResponseImmuneImmunityCd8b1 GeneMaintenanceIn VivoProteins
Grant awards (26)
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis$1,171,154
R01 · FY2025 · AI · contact PI
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis$595,577
R01 · FY2024 · AI · contact PI
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis$595,577
R01 · FY2023 · AI · contact PI
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis$595,577
R01 · FY2022 · AI · contact PI
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$472,668
R01 · FY2021 · AR
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2020 · AR
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2019 · AR
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$370,510
R01 · FY2019 · AR
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2018 · AR
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$394,132
R01 · FY2018 · AR
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2017 · AR
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$420,971
R01 · FY2017 · AR
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$451,473
R01 · FY2016 · AR
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$486,132
R01 · FY2015 · AR
Use of Substance P antagonists to regulate the skin immune function$348,941
R01 · FY2013 · AI · contact PI
Use of Substance P antagonists to regulate the skin immune function$371,213
R01 · FY2012 · AI · contact PI
Use of Substance P antagonists to regulate the skin immune function$371,213
R01 · FY2011 · AI · contact PI
Use of Substance P antagonists to regulate the skin immune function$374,963
R01 · FY2010 · AI · contact PI
Use of Substance P antagonists to regulate the skin immune function$374,270
R01 · FY2009 · AI · contact PI
Use of Adjuvants to Improve Skin Genetic Immunizations$256,287
R01 · FY2008 · CA · contact PI
Use of Adjuvants to Improve Skin Genetic Immunizations$256,389
R01 · FY2007 · CA · contact PI
Use of Adjuvants to Improve Skin Genetic Immunizations$264,149
R01 · FY2006 · CA · contact PI
Use of Adjuvants to Improve Skin Genetic Immunizations$270,607
R01 · FY2005 · CA
Immune role of CD14+ &CD14- human skin dendritic cells$222,750
R21 · FY2005 · AI
Use of Adjuvants to Improve Skin Genetic Immunizations$263,487
R01 · FY2004 · CA
Immune role of CD14+ &CD14- human skin dendritic cells$222,938
R21 · FY2004 · AI